Skip to main content
SpringerLink
Log in

First International Moxifloxacin Symposium

Berlin, 1999

  • Conference proceedings
  • © 2000

Overview

Editors:
  1. Lionel Mandell

    1. Division of Infectious Diseases Henderson General Hospital, McMaster University, Hamilton, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (36 papers)

  1. Front Matter

    Pages I-XIII
    Download chapter PDF

  2. Introduction to the Symposium

    1. Introduction to the Symposium

      • Lionel Mandell
      Pages 1-3

  3. Antimicrobial Chemotherapy

    1. Front Matter

      Pages 5-5
      Download chapter PDF

    2. Antimicrobial Chemotherapy — Today

      • John David Williams
      Pages 7-11

    3. Antimicrobial Chemotherapy—Tomorrow

      • Hartmut Lode
      Pages 12-18

  4. Pre-clinical

    1. Front Matter

      Pages 19-19
      Download chapter PDF

    2. Pre-clinical Microbiology — Streptococcus Pneumoniae

      • Regine Hakenbeck
      Pages 21-26

    3. Pre-clinical Microbiology — Gram-positive Cocci

      • Silvano Esposito
      Pages 27-30

    4. Pre-clinical Microbiology—Atypical Organisms

      • Cécile M. Bébéar
      Pages 31-35

    5. Pre-clinical Microbiology — Summary I

      • Bernd Wiedemann
      Pages 36-36

    6. Pre-clinical Microbiology — Mycobacteria

      • Stephen H. Gillespie
      Pages 37-42

    7. In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria

      • Ellie Goldstein
      Pages 43-48

    8. Pre-clinical Microbiology — Fastidious Gram-negative Bacteria

      • Adolf Bauernfeind
      Pages 49-53

    9. Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — USA

      • Daniel Sahm
      Pages 54-58

    10. Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — Europe

      • David Felmingham
      Pages 59-66

    11. Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — Japan

      • Kazunori Tomono
      Pages 67-74

    12. Mechanisms of Fluoroquinolone Action and Resistance

      • Karl Drlica
      Pages 75-83

    13. Pre-clinical Microbiology — Summary II

      • Bernd Wiedemann
      Pages 84-85

  5. Pharmacology

    1. Front Matter

      Pages 87-87
      Download chapter PDF

    2. Pharmacokinetics and Pharmacodynamics of Antimicrobials

      • Richard Wise
      Pages 89-93
Back to top

Keywords

About this book

5t The 1 International Moxifloxacin symposium took place in Berlin Germany February 18 - 20,1999. The purpose of this meeting was to introduce the medical and scientific communities to this exciting new fluoroquinolone and to define its role in the management of respiratory tract infections. The fluoroquinolones as a class are an important part of our therapeutic armamentarium and moxi­ floxacin is a unique addition to this class of compounds. This symposium brought together physician/scientists from around the world to present and discuss the moxifloxacin data. The information from this important meeting are presented in these proceedings and are organized under the following headings: Part I Antimicrobial chemotherapy Part II Pre-clinical microbiology Part III Pharmacology Part IV Clinical needs in the millennium Part V Round table discussion The modifications to the basic quinolone structure resulting in moxifloxacin have produced a drug with unique in vitro, and pharmacokinetic/pharmaco­ dynamic properties. The drug has a very broad spectrum of antimicrobial activity, is well absorbed and can be taken only once daily. Its profile makes it an excellent therapeutic option for many types of respiratory tract infections. It is hoped that our clinical and laboratory colleagues will be as excited by this data as we are and we look forward to further work with this unique and interesting compound.

Editors and Affiliations

  • Division of Infectious Diseases Henderson General Hospital, McMaster University, Hamilton, Canada

    Lionel Mandell

Bibliographic Information

  • Book Title: First International Moxifloxacin Symposium

  • Book Subtitle: Berlin, 1999

  • Editors: Lionel Mandell

  • DOI: https://doi.org/10.1007/978-3-642-59681-0

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 2000

  • Softcover ISBN: 978-3-642-64081-0Published: 14 February 2012

  • eBook ISBN: 978-3-642-59681-0Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XIII, 191

  • Topics: Internal Medicine

Publish with us

Policies and ethics

Back to top

Search

Navigation